Specialty biopharmaceutical company Adamis Pharmaceuticals Corp. (ADMP) announced it has submitted a fast-track application for Tempol to the U.S. Food and Drug Administration (FDA), earlier this week.
The drug is being developed for the treatment and prevention of COVID-19 and is currently in a Phase 2/3 clinical trial in patients affected by COVID-19.
Importantly, Tempol has demonstrated antiviral, anti-inflammatory, and antioxidant activity. While there have been recent approvals for oral antiviral drugs, Adamis noted Tempol’s unique mechanism of action and safety profile would offer an unmet medical requirement.
With this development in mind, let us take a look at the changes in Adamis’ key risk factors that investors should know.
According to the TipRanks Risk Factors tool, Adamis Pharma’s top risk category is Finance & Corporate, contributing 41% (compared to a sector average of 29%) to the total 63 risks identified. In its recent quarterly report, the company has added one key risk factor under the Tech & Innovation risk category.
Adamis noted that developing new pharmaceutical products is a risky activity. There can be no guarantee if R&D efforts or clinical trials would fructify into viable products or satisfy safety standards.
Keeping a tab on insiders stocks can provide timely insights for retail investors. TipRanks data on Insider Activity points that insiders have sold Adamis Pharma shares worth $115.2 thousand in the last three months, indicating a very negative insider confidence signal for the stock based on 4 insider transactions in the last 3 months.
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Download the TipRanks mobile app now